



<b>Median proposed drugs for the 2 groups</b>	<b>3 (3-5)</b>
<b>NRTI</b>	<b>2 (0-3)</b>
<b>NNRTI</b>	<b>0 (0-1)</b>
<b>PI</b>	<b>1 (0-2)</b>

<b>DETERMINATION OF PI AND/OR NNRTI PLASMA CONCENTRATIONS (HPLC)</b>				
(% of patients)	Group Geno		Group GenoPhar	
	Adequate	Low	Adequate	Low
<b>D0</b>	<b>87%</b>	<b>13%</b>	<b>82%</b>	<b>18%</b>
<b>W8</b>	<b>74%</b>	<b>16%</b>	<b>79%</b>	<b>21%</b>
<b>W12</b>	<b>73%</b>	<b>27%</b>	<b>76%</b>	<b>24%</b>
<b>W18</b>	<b>76%</b>	<b>24%</b>	<b>73%</b>	<b>27%</b>
<b>W24</b>	<b>72%</b>	<b>28%</b>	<b>83%</b>	<b>17%</b>

Steady-state plasma concentrations were classified as adequate or low, according to the respective in vitro concentrations of drugs needed to inhibit viral replication by 50/90% corrected by the protein binding.

<b>VIROLOGICAL AND IMMUNOLOGICAL EFFICACY AT WEEK 12 AND 24</b> (* By ITT missing equal failure analysis)			
<b>Week 12</b>			
	<b>Group G (n=67)</b>	<b>Group GP (n=67)</b>	<b>p</b>
<b>HIV-1 RNA &lt; 200 cp/ml*</b>	<b>30/67 (45%)</b>	<b>29/67 (43%)</b>	<b>0.86</b>
<b>Δ HIV-1 RNA: W12-D0 Log10 cp/ml</b>	<b>-1.3 (-2.9 to 0.7)</b>	<b>-1.4 (-2.9 to 0.8)</b>	<b>0.41</b>
<b>Δ CD4 cell counts : W12-D0 (/mm3)</b>	<b>49 (-583 to 299)</b>	<b>29 (-268 to 620)</b>	<b>0.27</b>
<b>Week 24</b>			
	<b>Group G (n=67)</b>	<b>Group GP (n=67)</b>	<b>p</b>
<b>HIV-1 RNA &lt; 200 cp/ml*</b>	<b>35/67 (52%)</b>	<b>40/67 (60%)</b>	<b>0.38</b>
<b>Δ HIV-1 RNA: W24-D0 Log10 cp/ml</b>	<b>-1.3 (-3.1 to 1.4)</b>	<b>-1.5 (-2.9 to 0.7)</b>	<b>0.56</b>
<b>Δ CD4 cell counts : W24-D0 (/mm3)</b>	<b>75 (-204 to 524)</b>	<b>63 (-239 to 620)</b>	<b>0.51</b>

In multivariate analysis, sex, time on ART, HIV-1 RNA level and No of mutated positions at baseline, treatment proposed at W4, plasma concentrations at W8 and W12, were not associated with viral load suppression < 200 cp/ml at W12.

**CONCLUSION**

This study shows that combining genotypic resistance testing with the advice from an expert committee that monitors individual subsequent therapy in patients with multiple resistance mutations, was associated with a high antiviral efficacy : 62% of patients (as observed) and 56% (ITT analysis) had < 200 cp/ml at week 24. The benefit of using TDM was not evidenced in this study in which patients appeared highly compliant.